

THE LANCET

Gastroenterology & Hepatology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Abeysekera KWM, Fernandes GS, Hammerton G, et al.
Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.
Lancet Gastroenterol Hepatol 2020; published online Jan 15. [https://doi.org/10.1016/S2468-1253\(19\)30419-4](https://doi.org/10.1016/S2468-1253(19)30419-4).

Variable		Fibrosis Score with IQR/M <30%	Fibrosis Scores with IQR/M ≥30%	P value
CAP Score (dB/m)	Median (IQR)	203.0 (173.0-238.0)	230.5 (180.0-264.0)	p=0.0017*
BMI (kg/m ²)	Median (IQR)	23.7 (21.5-26.7)	27.6 (23.3-33.4)	p<0.0001‡
Waist circumference-to-Height Ratio	Median (IQR)	0.46 (0.43-0.50)	0.51 (0.44-0.59)	p<0.0001‡
ALT (10-35U/l)	Median (IQR)	20.5 (15.3-29.2)	19.6 (14.6-33.7)	p=0.91‡
AST (10-35U/l)	Median (IQR)	24.1 (20.6-29.2)	23.3 (20.0-28.6)	p=0.34‡
GGT (<40 U/l)	Median (IQR)	16.0 (12.0-22.0)	16.0 (13.0-21.0)	p=0.76‡
HOMA-IR (<1.68)	Median (IQR)	1.72 (1.20-2.53)	2.36 (1.61-3.59)	p<0.0001‡
Cholesterol (<5.2mmol/l)	Median (IQR)	4.3 (3.9-4.9)	4.5 (4.0-4.9)	p=0.42*
Triglycerides (<1.7mmol/l)	Median (IQR)	0.8 (0.6-1.1)	0.9 (0.7-1.2)	p=0.69‡
LDL (mmol/l)	Median (IQR)	2.4 (1.9-2.9)	2.5 (2.0-2.9)	p=0.47*
VLDL (mmol/l)	Median (IQR)	0.4 (0.3-0.5)	0.4 (0.3-0.5)	p=0.69‡
HDL (>1.45mmol/l)	Median (IQR)	1.5 (1.3-1.8)	1.6 (1.3-1.8)	p=0.82*
Metabolic Syndrome (≥3 of 5 criteria)	n=172	162 (9.9%)	10 (28.6%)	p<0.0001

* Two sample t test

‡ Mann-Whitney Test

Footnote: CAP: controlled attenuation parameter; HOMA-IR: homeostatic model assessment of insulin resistance; metabolic syndrome criteria (≥3 of 5 criteria): (1) Male waist circumference ≥102cm or female waist circumference ≥88cm. (2) Triglyceride level ≥1.7mmol/l. (3) HDL in men <1.93mmol or in women <1.3mmol/l. (4) Systolic blood pressure ≥130mmHg or diastolic blood pressure ≥85mmHg. (5) Fasting glucose ≥5.6mmol/l